Syros Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing novel therapies in oncology, with a historical emphasis on hematologic malignancies. The company was incorporated in 2011 and changed its name to Syros Pharmaceuticals, Inc. in August 2012. It is headquartered in Cambridge, Massachusetts, United States. Syros traded on the Nasdaq Global Select Market under the ticker SYRS, but in February 2025 the company announced a voluntary delisting from Nasdaq and deregistration with the SEC as part of an orderly wind-down of the business. For investors, that is a critical framing point: Syros remains a U.S. healthcare name, but its public-market and operating profile shifted materially in 2025. ([d1io3yog0oux5.cloudfront.net](https://d1io3yog0oux5.cloudfront.net/_d68c9e0bb36396b16cecd23a67cde8d6/syros/news/2025-02-28_Syros_Announces_Voluntary_Delisting_from_Nasdaq_313.pdf)) Operationally, Syros built its research platform around controlling gene expression, aiming to discover medicines for patient subsets defined by specific biological and genomic features. Its best-known clinical asset has been tamibarotene, an oral selective RARα agonist studied in higher-risk myelodysplastic syndrome patients with RARA overexpression. The company also developed additional pipeline assets, including SY-2101 and SY-5609; the latter is an oral, selective CDK7 inhibitor that entered clinical testing in select solid tumors. This makes Syros a classic specialty biotech: science-driven, highly R&D-intensive, and dependent on clinical validation rather than commercial revenues. ([d1io3yog0oux5.cloudfront.net](https://d1io3yog0oux5.cloudfront.net/_d68c9e0bb36396b16cecd23a67cde8d6/syros/news/2025-02-28_Syros_Announces_Voluntary_Delisting_from_Nasdaq_313.pdf)) From a competitive standpoint, Syros operated in a very crowded and capital-intensive oncology biotech landscape, where larger or better-funded peers often have broader pipelines, deeper cash resources, and stronger partnering leverage. Syros’ strategy was differentiated by precision oncology and gene-regulation biology, but the company’s development risk remained substantial. In February 2025, Syros disclosed that its SELECT-MDS-1 Phase 3 trial of tamibarotene plus azacitidine failed to meet its primary endpoint of complete response rate. The company linked that outcome to an event of default under its loan agreement with Oxford Finance and stated that it had agreed to operate as a wind-down business, limiting spending under an Oxford-approved budget. ([d1io3yog0oux5.cloudfront.net](https://d1io3yog0oux5.cloudfront.net/_d68c9e0bb36396b16cecd23a67cde8d6/syros/news/2025-02-28_Syros_Announces_Voluntary_Delisting_from_Nasdaq_313.pdf)) In geographic terms, Syros is a Massachusetts-based U.S. biotech with no meaningful commercial footprint to highlight; its presence has been centered in Cambridge and in clinical-development activities. Its recent history is best understood as a company moving from an innovation-led oncology platform to an orderly capital-preservation phase, rather than a near-term commercialization story. For French-speaking investors, Syros therefore fits the profile of a high-risk U.S. micro-/small-cap biotech on Nasdaq that has transitioned into delisting and wind-down mode. ([d1io3yog0oux5.cloudfront.net](https://d1io3yog0oux5.cloudfront.net/_d68c9e0bb36396b16cecd23a67cde8d6/syros/news/2025-02-28_Syros_Announces_Voluntary_Delisting_from_Nasdaq_313.pdf))